Erectile Dysfunction Pipeline Drugs and Therapeutics Market H2 2017 Available at RnR Market Research

USA - English

• India - English

PUNE, India, July 21, 2017 /PRNewswire/ --

Erectile Dysfunction Pipeline Drugs and Therapeutics Market H2 2017 report provides latest therapeutics and drugs development for Erectile Dysfunction by major key players with their dormant and discontinued project. Complete report on Erectile Dysfunction - Pipeline Review, H2 2017 spread across 112 pages is available at http://www.rnrmarketresearch.com/erectile-dysfunction-pipeline-review-h2-2017-market-report.html.

Erectile Dysfunction Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Erectile Dysfunction Drugs (Male Health) complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer. Order a copy of this research report at
http://www.rnrmarketresearch.com/contacts/purchase?rname=1141789.

The Erectile Dysfunction (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 2, 4, 5, 3, 2, 13, 3 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Companies discussed in this report include  Apricus Biosciences Inc , Astellas Pharma Inc , Biolab Farmaceutica Ltda , Biopharm GmbH , Can-Fite BioPharma Ltd , Fabre-Kramer Pharmaceuticals Inc , Futura Medical Plc , Hanmi Pharmaceuticals Co Ltd , Humanetics Corp , IntelGenx Corp , Ion Channel Innovations LLC , iX Biopharma Ltd , Mezzion Pharma Co Ltd, Mitsubishi Tanabe Pharma Corp , Monosol Rx LLC , N4 Pharma Plc , NAL Pharmaceuticals Ltd , Nanoform Cardiovascular Therapeutics Ltd , Palatin Technologies Inc , Pharmicell Co Ltd , SK Chemicals Co Ltd , Suda Ltd , XuanZhu Pharma Co Ltd , Yangtze River Pharmaceutical Group , Yungjin Pharm Co Ltd.

Drug Profile Discussed In Report: alprostadil , AP-185 , avanafil , BIO-300 , BL-214 , Cellgram-ED , CF-602 , fadanafil , FKK-01PD , HCP-1302 , IPED-2015 , MED-2002 , MED-2005 , mirabegron ER , moxisylyte , Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Male Health , pVAX-hSlo , Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease , sildenafil , sildenafil citrate , sildenafil citrate , sildenafil citrate , sildenafil citrate , Small Molecule to Inhibit PDE5 for Erectile Dysfunction , SUD-003 , Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction , T-6932 , tadalafil , tadalafil , tadalafil , tadalafil , tadalafil , TF-0092 , TPN-729 , TR-399 , udenafil , YBH-1603 , Yonkenafil.

Related reports on Erectile Dysfunction:  

Erectile Dysfunction - Epidemiology Insights to 2025

Erectile Dysfunction - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Erectile Dysfunction in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Erectile Dysfunction prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Erectile Dysfunction. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by team of industry experts.

Explore more reports of Therapeutics Market Research at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics.

About Us:  

RnRMarketResearch.com is your one stop market research and industry analysis reports' library providing business data and intelligence information on thousands of micro markets with global as well as regional coverage. Category focused research, country reports, company profiles, regional and global industry profiles and guides to premium reports offering extensive coverage of other 20+ industries are all available in our library of syndicated market research reports.

Contact:
Ritesh Tiwari
2nd Floor, Metropole,
Bund Garden Road,
Pune - 411001,
India.
Tel: +1-888-391-5441
E-mail: [email protected]

SOURCE RnRMarketResearch